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IG. sownbliet: Therapy for heart failure Em8hS COldrO- 
~~attdvariablyefktivebecauseoneisdealingwitha 
~prof2es0hatbqjnswithcardiacdamagee,ofteni~ 
dekd;resuhsinco~changesintheh~~ 
&c&ion that may be inadequate or counterproductive; 
andendswithcircuMoryand~dysfunction~pro- 
duces disability or death. Without clear deliueation f the 
pathophysiolqy,theresultswillremainhmited.Itishnpor- 
tatit o remember that people generally observe only what 
theirideasplupiuethemtoObserVe. 
Iwouldproposethefoll~modelkeepiriginmindthat 
heart Gbue is a time-depefknt process. The initiat@ 
eventsofheartfaihuemaybeabnormaloverloadorlmiden- 
tified vhuses or toxins, but aging (with its loss of myocytes) 
contributes to the process. About H of 1% of our cardii 
cellsarelosteachyear.Illeremainiicmdiacceusbearan 
iacressedloadandinresponsetothisload,theybecome 
hypertropbied, aprocessf&wred soon there&r by vascu- 
lar remodeliqs. These processes are amplkd and acceler- 
ated by activatiou f the neurohormonal systems. Hype* 
phiedceuscontmctandrelaxmoreslowly,pIwvidingthe 
basisfordiastoiicventriculardysfun&m.Onthebasisof 
this model, it would seem that we can alter the evob~tion of 
this process only by preset& myocytes. 
Buthowcanweachievethisgoalifwedonothavethe 
~tmodeltostudynew~?~we~outcillic~ 
studies,wehavetoknowwhatwearetreat&butwedonot 
knowwhatthetatgetis.Canindushydevelopdrugssuc- 
cessfuUy ifitdoes not have an appropriate pathophysiologic 
model? 
J. AIexauk Dr. Sonnenblick, thepharmawutical indus- 
try is very pmgmatic. This view explains why it is very 
ditRcult for any company to embark on the development of 
inotropicdNgs.Althoughtherearemanypalkntswithheart 
faihue,thesalesdeventhemostsuccessfuldrugsfoaheart 
fakeareintherangeofonlyS3BmiUionayear.Thatmay 
aoundlikealargeamountofmoney,butthatamountcanbe 
Ewoduced by many other successful drugs that we could 
dmelopwithoutincurringthesamerisk.Unlessthereisa 
clearkapeutictarget,itisverydiitocommitthe 
==rcesneededforconductoflaIgescaleclinicaltrials. 
E. ~bIi& In several experimental models, vera- 
pamil favorably affected the natural history of the disease by 
inhibiting microvascular spasm. Would industry invest in a 
drug like vempamil that could permit us to address the real 
probkm of heart failure? 
J. AIexamk Verapamil is an excellent lead, and leads 
help us to develop a target and a concept. For example, the 
rwnodeling hypothesis of lks. Marc and Janice pfeffer, 
based on the results of the animal models and pilot studies, 
permitted usto ask the management of the wmpauy to 
commit $16 million to conduct the SAVE study. The dem- 
ons ration forthe elkacy of drug in an animal model greatly 
enhances our ability to bring new drugs fonnrard to clinical 
development. 
R &nnsnhIklu Ilr. Rouleau, what animal models exist 
that will permit us to test our hypotheses? 
J. Reukaw I do not think that here is a good animal 
mod l of heart failure. Many models have been developed 
(pacing model in the dog, aortic bauding inthe puppy and 
coronary ligation model in the rat) but all these models have 
important limitations. 
I would l&e to suggest wncepts for two clinical trials that 
re not currently being planned orcarried out. First, studies 
should be carried out to evaluate he effect of er@tensin- 
converting enzyme inhrbitors (and other drugs) in the eld- 
erly. Heart failure is a disease of the elderly but most 
elderly patients are not enrolled in clinical trials of new 
drugsforheartIkihue.Suchtrialsareimportantbecause 
heartfaihue in the elderly is diikent from heart failure 
in the young. The hearts d elderly patients are hyper- 
trophii and fibrotic, not dilated and hypocontractile, so the 
response of older patients odrugs may be very different 
from the &ect seen in younger patients. Second, studies 
should be carried out on the utility of beta-blockers in 
patients with heart failure associated with wuuuuy artery 
disease.We know that beta-blacken are useful in patients 
with left ventricular dysfunction shortly after their myocar- 
dialin&tion,butwedonotknowtheutilityofbeta- 
blockade in patients with coronary artery disease who 
Ez&v~ed heart fake mauy ears after their 
. . 
. 
P.~WgsezIbetievethatinthenexttkwyearswe 
will be able to identify patients who will benefit the most 
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from specik interventions. This represent.5 he greatest 
challenge that we currently have with existing treatments. 
However, major advances in therapeutics will come not 
from present drugs but from the new biology. New drugs will 
be directed toward the control of myocardial hypertrophy 
and other abnormal growth processes. 
E. Souuw~bIidu One of the important challenges is con- 
vincing physicians not only to use effective drugs but to use 
them in effective doses. Many physicians use only one third 
or one quarter of the doses of angiotensin-converting en- 
zyme inhi&itors used in cliniial trials. Some physicians even 
believe that 2.5 mg of enalapril s effective and very ftiw 
BSA 
physicians will prescribe 50 mg of captopril three times 
daily, even after the SAVE trial is published. This is an 
important issue. 
J. Alexander: Yes, I think that dosage an important issue. 
In the development of captopril, we selected oses of the 
drug that were large nough to block aldosterone production 
maximaUy,whichrequhed5Omgofthedrugthreetimes 
daily.Iamnotsurethatlowerdoseswillbeaseffectiveas 
higher doses. Perhaps the ATLAS study (which will com- 
parethee&acyandsafetyofhiqhandiowdosesof 
angiotensin-converting enzyme inhibitor@ will help us to 
address this question. 
